Program
SAL0140
A development code. Also written as “SAL0140 Tablets”.
Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism, led by Shenzhen Salubris Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 44 open or running | phase 2since Jun 8, 2026 | Jun 17, 2025 | Mar 1, 2027phase 2 · NCT07654140 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2025First study: phase 1 study in Uncontrolled HypertensionFirst studyNCT07051603 · 82 planned · China
- Jun 8, 20263 phase 2 studiesPhase 2 reachedNCT07646535, NCT07647133, NCT07654140
Ahead
- Mar 1, 2027Primary completion: phase 2 study in HypertensionNCT07654140
- Apr 1, 2027Primary completion: phase 2 study in HyperaldosteronismNCT07646535
- Oct 8, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07647133
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07654140Hypertension · China | 2 | Recruiting | Mar 1, 2027 | 252 |
| NCT07647133Renal Insufficiency, Chronic · China | 2 | Not yet recruiting | Oct 8, 2027 | 249 |
| NCT07646535Hyperaldosteronism · China | 2 | Not yet recruiting | Apr 1, 2027 | 50 |
| NCT07051603Uncontrolled Hypertension · China | 1 | Recruiting | Jan 2026 | 82 |
How it is read
Names in the registry
- “SAL0140”, 4 entries
- “SAL0140 Tablets”, 4 entries
Codes read as this program: SAL0140.
Conditions, from the studies’ own filings
- Hypertension, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Hyperaldosteronism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.